The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Evaluation of a Mouse Model of Necrotic Granuloma Formation Using C3HeB/FeJ Mice for Testing of Drugs against Mycobacterium tuberculosis
Open accessAbstract
Persistence of Mycobacterium tuberculosis remains a significant challenge for the effective treatment of tuberculosis in humans. In animals that develop necrotic lung lesions following infection with M. tuberculosis , drug-tolerant bacilli are present and persist in an extracellular microenvironment within the necrotic cores. In this study, we examined the efficacy of drug treatment in C3HeB/FeJ (Kramnik) mice that develop lesions with liquefactive necrosis, in comparison to BALB/c mice that develop nonnecrotic lesions following aerosol challenge. To accomplish this, Kramnik and BALB/c mice were infected by aerosol with M. tuberculosis and treated for 7 to 8 weeks with monotherapy using drugs with different modes of action. The efficacy of drug therapy was quantified by enumeration of bacterial load. The progression of disease and location and distribution of bacilli within lesions were visualized using various staining techniques. In the late stages of infection, Kramnik mice developed fibrous encapsulated lung lesions with central liquefactive necrosis containing abundant extracellular bacilli, whereas BALB/c mice formed nonnecrotic lesions with primarily intracellular bacilli. Necrotic lesions in Kramnik mice showed evidence of hypoxia by pimonidazole staining. Kramnik mice were significantly more refractory to drug therapy, especially for pyrazinamide. Metronidazole showed no bactericidal activity in either model. There were significantly higher numbers of drug-resistant colonies isolated from the Kramnik mice compared to BALB/c mice. These results suggest that the Kramnik mouse model will be a valuable model to test antituberculosis drugs, especially against bacilli that persist within necrotic lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1968) · Medical Entomology and Zoology · Cited by 4,924
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
Foamy macrophages and the progression of the human tuberculosis granuloma
Russell, D. G., Cardona, P.-J., Kim, M.-J., Allain, S., & Altare, F. (2009) · Nature Immunology · doi:10.1038/ni.1781 · Cited by 827
Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates
Via, L. E., Lin, P. L., Ray, S. M., Carrillo, J., Allen, S. S., Eum, S. Y., Taylor, K., Klein, E., Manjunatha, U., Gonzales, J., et al. (2008) · Infection and Immunity · doi:10.1128/iai.01515-07 · Cited by 664
The curious characteristics of pyrazinamide: a review.
Zhang, Y., & Mitchison, D. A. (2003) · PubMed · Cited by 586
Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism
Kim, M., Wainwright, H. C., Locketz, M., Bekker, L., Walther, G. B., Dittrich, C., Visser, A., Wang, W., Hsu, F., Wiehart, U., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000079 · Cited by 489
Ipr1 gene mediates innate immunity to tuberculosis
Pan, H., Yan, B.-S., Rojas, M., Shebzukhov, Y. V., Zhou, H., Kobzik, L., Higgins, D. E., Daly, M. J., Bloom, B. R., & Kramnik, I. (2005) · Nature · doi:10.1038/nature03419 · Cited by 480
Self-citationFord, C. B., Lin, P. L., Chase, M. R., Shah, R. R., Iartchouk, O., Galagan, J., Mohaideen, N., Ioerger, T. R., Sacchettini, J. C., Lipsitch, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.811 · Cited by 437
Tsai, M. C., Chakravarty, S., Zhu, G., Xu, J., Tanaka, K., Koch, C., Tufariello, J., Flynn, J., & Chan, J. (2006) · Cellular Microbiology · doi:10.1111/j.1462-5822.2005.00612.x · Cited by 414
Mycobacterium tuberculosis Growth at theCavity Surface: a Microenvironment with FailedImmunity
Kaplan, G., Post, F. A., Moreira, A. L., Wainwright, H., Kreiswirth, B. N., Tanverdi, M., Mathema, B., Ramaswamy, S. V., Walther, G., Steyn, L. M., et al. (2003) · Infection and Immunity · doi:10.1128/iai.71.12.7099-7108.2003 · Cited by 350
Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis
Kramnik, I., Dietrich, W. F., Demant, P., & Bloom, B. R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.150227197 · Cited by 345
Self-citationDayan, D., Hiss, Y., Hirshberg, A., Bubis, J. J., & Wolman, M. (1989) · Histochemistry · doi:10.1007/bf00266843 · Cited by 327
Vernon, A., Burman, W., Benator, D., Khan, A., & Bozeman, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11467-8 · Cited by 308
Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., & Orme, I. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2294-2301.2005 · Cited by 306
Self-citationSchnoor, M., Cullen, P., Lorkowski, J., Stolle, K., Robenek, H., Troyer, D., Rauterberg, J., & Lorkowski, S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5707 · Cited by 298
Prideaux, B., Dartois, V., Staab, D., Weiner, D. M., Goh, A., Via, L. E., Barry, C. E., & Stoeckli, M. (2011) · Analytical Chemistry · doi:10.1021/ac1029049 · Cited by 260
Hypoxia: a window into Mycobacterium tuberculosis latency
Rustad, T. R., Sherrid, A. M., Minch, K. J., & Sherman, D. R. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01325.x · Cited by 252
Li, M., Riddle, S. R., Frid, M. G., El Kasmi, K. C., McKinsey, T. A., Sokol, R. J., Strassheim, D., Meyrick, B., Yeager, M. E., Flockton, A. R., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100479 · Cited by 239
Early Events in Mycobacterium tuberculosis Infection in Cynomolgus Macaques
Lin, P. L., Pawar, S., Myers, A., Pegu, A., Fuhrman, C., Reinhart, T. A., Capuano, S. V., Klein, E., & Flynn, J. L. (2006) · Infection and Immunity · doi:10.1128/iai.00064-06 · Cited by 233
Replication Dynamics of Mycobacterium tuberculosis in Chronically Infected Mice
Muñoz-Elías, E. J., Timm, J., Botha, T., Chan, W.-T., Gomez, J. E., & McKinney, J. D. (2005) · Infection and Immunity · doi:10.1128/iai.73.1.546-551.2005 · Cited by 226
CANETTI, G. (1956) · The American Journal of the Medical Sciences · doi:10.1097/00000441-195604000-00012 · Cited by 219
Oxygen status of lung granulomas in Mycobacterium tuberculosis‐infected mice
Aly, S., Wagner, K., Keller, C., Malm, S., Malzan, A., Brandau, S., Bange, F., & Ehlers, S. (2006) · The Journal of Pathology · doi:10.1002/path.2055 · Cited by 185
Pathology of postprimary tuberculosis in humans and mice: Contradiction of long-held beliefs
Hunter, R. L., Jagannath, C., & Actor, J. K. (2007) · Tuberculosis · doi:10.1016/j.tube.2006.11.003 · Cited by 179
Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions
Kjellsson, M. C., Via, L. E., Goh, A., Weiner, D., Low, K. M., Kern, S., Pillai, G., Barry, C. E., & Dartois, V. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05208-11 · Cited by 164
Acquired Rifamycin Resistance with Twice-Weekly Treatment of HIV-related Tuberculosis
Burman, W. J., Benator, D., Vernon, A. A., Khan, A., Jones, B., Silva, C., Lahart, C., Weis, S. E., King, B., Mangura, B. T., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200503-417oc · Cited by 154
Hoff, D. R., Ryan, G. J., Driver, E., Ssemakulu, C. C., Groote, M. A. D., Basaraba, R. J., & Lenaerts, A. J. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017550 · Cited by 142
Self-citationDavis, S. L., Nuermberger, E. L., Um, P. K., Vidal, C., Jedynak, B., Pomper, M. G., Bishai, W. R., & Jain, S. K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00789-09 · Cited by 134
Pichugin, A. V., Yan, B., Sloutsky, A., Kobzik, L., & Kramnik, I. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.081075 · Cited by 134
Self-citationBasaraba, R. J. (2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70035-0 · Cited by 128
Self-citationProspects for Clinical Introduction of Nitroimidazole Antibiotics for the Treatment of Tuberculosis
Barry, C. E., Boshoff, H. I., & Dowd, C. S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383214 · Cited by 128
The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome
Manabe, Y. C., Kesavan, A. K., Lopez-Molina, J., Hatem, C. L., Brooks, M. E., Fujiwara, R. T., Hochstein, K., Pitt, M. L. M., Tufariello, J. M., Chan, J., et al. (2007) · Tuberculosis · doi:10.1016/j.tube.2007.10.006 · Cited by 114
The mouse as a useful model of tuberculosis
Orme, I. M. (2003) · Tuberculosis · doi:10.1016/s1472-9792(02)00069-0 · Cited by 109
Lessons From a Proficiency Testing Event for Acid-Fast Microscopy
Somoskövi, Á., Hotaling, J. E., Fitzgerald, M., et al. (2001) · CHEST Journal · doi:10.1378/chest.120.1.250 · Cited by 109
Ahmad, Z., Klinkenberg, L. G., Pinn, M. L., Fraig, M., Peloquin, C. A., Bishai, W. R., Nuermberger, E. L., Grosset, J. H. E., & Karakousis, P. C. (2009) · The Journal of Infectious Diseases · doi:10.1086/605605 · Cited by 108
Role of cholesterol in Mycobacterium tuberculosis infection.
Miner, M. D., Chang, J. C., Pandey, A. K., Sassetti, C. M., & Sherman, D. R. (2009) · PubMed · Cited by 103
Ehlers, S. (2009) · Infection · doi:10.1007/s15010-009-8450-7 · Cited by 94
Metronidazole Therapy in Mice Infected with Tuberculosis
Brooks, J. V., Furney, S. K., & Orme, I. M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1285 · Cited by 92
Ryan, G. J., Hoff, D. R., Driver, E., Voskuil, M. I., Juarrero, M. G., Basaraba, R. J., Crick, D. C., Spencer, J. S., & Lenaerts, A. J. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011108 · Cited by 85
Self-citationEvaluation of Standard Chemotherapy in the Guinea Pig Model of Tuberculosis
Ordway, D. J., Shanley, C. A., Caraway, M. L., Orme, E. A., Bucy, D. S., Hascall-Dove, L., Henao-Tamayo, M. I., Harton, M. R., Shang, S., Ackart, D. F., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01521-09 · Cited by 81
Self-citationAnaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis
Wade, M. M., & Zhang, Y. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45639-0 · Cited by 80
Kramnik, I. (2008) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-75203-5_6 · Cited by 74
Self-citationNedeltchev, G. G., Raghunand, T. R., Jassal, M. S., Lun, S., Cheng, Q. J., & Bishai, W. R. (2008) · Infection and Immunity · doi:10.1128/iai.01132-08 · Cited by 70
Yan, B., Pichugin, A. V., Jobe, O., Helming, L., Eruslanov, E. B., Gutierrez-Pabello, J. A., Rojas, M., Shebzukhov, Y. V., Kobzik, L., & Kramnik, I. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6919 · Cited by 61
Self-citationKeller, C., Lauber, J., Blumenthal, A., Buer, J., & Ehlers, S. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.12.003 · Cited by 60
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis.
Dhillon, J., Allen, B. W., Hu, Y., Coates, A. R. M., & Mitchison, D. A. (1998) · PubMed · Cited by 57
Ahmad, Z., Fraig, M., Bisson, G. P., Nuermberger, E. L., Grosset, J. H. E., & Karakousis, P. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01524-10 · Cited by 54
Shang, S., Shanley, C. A., Caraway, M. L., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00978-10 · Cited by 51
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig
Ahmad, Z., Nuermberger, E. L., Tasneen, R., Pinn, M. L., Williams, K. N., Peloquin, C. A., Grosset, J. H. E., & Karakousis, P. C. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq007 · Cited by 50
Jain, S. K., Hernandez‐Abanto, S. M., Cheng, Q., Singh, P., Ly, L. H., Klinkenberg, L. G., Morrison, N. E., Converse, P. J., Nuermberger, E. L., Grosset, J. H. E., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/517526 · Cited by 45
Metronidazole Lacks Antibacterial Activity in Guinea Pigs Infected with Mycobacterium tuberculosis
Hoff, D. R., Caraway, M. L., Brooks, E. J., Driver, E., Ryan, G. J., Peloquin, C. A., Orme, I. M., Basaraba, R. J., & Lenaerts, A. J. M. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00196-08 · Cited by 40
Self-citationImmune Responses in Animal Models
Orme, I. M. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-80166-2_8 · Cited by 20
Early, M. A., Lishnevsky, M., Gilchrist, J. M., Higgins, D. M., Orme, I. M., Müller, W. A., Juarrero, M. G., & Schenkel, A. R. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.07.008 · Cited by 12
Cited by
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Dartois, V. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3200 · Cited by 388
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Lenaerts, A., Barry, C. E., & Dartois, V. (2015) · Immunological Reviews · doi:10.1111/imr.12252 · Cited by 362
Self-citationSilva Miranda, M., Breiman, A., Allain, S., Deknuydt, F., & Altare, F. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/139127 · Cited by 318
Gr1intCD11b+ Myeloid-Derived Suppressor Cells in Mycobacterium tuberculosis Infection
Obregón-Henao, A., Henao-Tamayo, M., Orme, I. M., & Ordway, D. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080669 · Cited by 74
Zinc limitation triggers anticipatory adaptations in Mycobacterium tuberculosis
Dow, A., Sule, P., O’Donnell, T. J., Burger, A., Mattila, J. T., Antonio, B., Vergara, K., Marcantonio, E., Adams, L. G., James, N., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009570 · Cited by 55
Metadata
- Authors
- Driver, E. R., Ryan, G. J., Hoff, D. R., Irwin, S. M., Basaraba, R. J., Kramnik, I., & Lenaerts, A. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-06
- Volume
- 56
- Issue
- 6
- Pages
- 3181-3195
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W1970610212
- Cited by
- 266
- References
- 52
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.